SAVA 2.35 (+2.62%)
US14817C1071BiotechnologyBiotechnology

Cassava Sciences (SAVA) Stock Highlights

2.35 | +2.62%
2024-12-21 04:11:40
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimers disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimers disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimers disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.

Statistics

Range Today
2.23 2.41
Volume Today 3.19M
Range 1 Year
2.28 42.2
Volume 1 Year 645.14M
Range 3 Year
2.28 62.49
Volume 3 Year 1.47B
Range 10 Year
0.76 146.16
Volume 10 Year 4.43B

Highlights

Market Capitalization 1.3B (small)
Floating Shares 42.79M
Current Price 2.35
Price To Earnings -18.12
Price To Book 8.28
Earnings Per Share -1.38
Payout Ratio 0%

Performance

Latest +2.62%
1 Month -91.65%
3 Months -92.35%
6 Months -87.94%
1 Year -91.59%
3 Years -94.5%
5 Years +16.34%
10 Years -83.7%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.